How to Apply the Brakes to a Sweet Storm Out of Control?
Every 8 seconds, someone in the world is diagnosed with diabetes. However, scientists have discovered that by supplementing the gut with the right bacteria, glycated hemoglobin can be reduced by an additional 0.5%.
The Silent Tsunami Behind the Numbers
* Global: 537 million patients, with 1 in 2 adults in the pre-diabetic stage.
* Economic: In 2023, global direct medical expenditure reached $966 billion, equivalent to Switzerland's GDP; 12% of China's medical insurance funds are allocated to diabetes and its complications.
Recent metagenomic research indicates that 90% of type 2 diabetes patients exhibit a significant deficiency in "butyrate-producing bacteria," leading to a compromised intestinal barrier, likened to a "sieve," allowing inflammatory factors to leak into the bloodstream.
Etiology: From "Pancreatic Strike" to "Intestinal Axis Failure"
Classic Chain:
Genetic predisposition + High-calorie diet + Sedentary lifestyle → Insulin resistance → β-cell failure
New Perspective on the Intestinal Axis:
* Imbalance: Decreased Firmicutes, increased Bacteroidetes, and a drastic reduction in short-chain fatty acid (butyrate, propionate) production.
* Consequences: Disruption of the intestinal barrier → LPS (endotoxin) enters the bloodstream → Chronic low-grade inflammation → "Inflammation switch" shuts down insulin signaling.
* Probiotic Deficit: The abundance of Bifidobacterium animalis, Akkermansia muciniphila, and Clostridium butyricum is reduced by an average of 50–70% in the feces of type 2 diabetes patients.
Complications: Beyond "Slightly Elevated Blood Sugar"
Acute: Ketoacidosis, hyperosmolar coma, with a mortality rate still exceeding 5%.
Chronic:
* Microvascular: Retinopathy → 1 in 3 cases of blindness are due to diabetic retinopathy; Nephropathy → 40% of dialysis patients are due to diabetes.
* Macrovascular: Increased risk of myocardial infarction and stroke by 2–4 times.
* Neuropathy: 60% of patients experience painful neuropathy, leading to foot ulcers → 1 amputation every 30 seconds.
* Psychological: The incidence of depression is twice that of normal individuals; diabetes + depression further increases the risk of death by 49%.
Recent Follow-up: Patients in the lowest quartile of gut microbiota diversity have a 42% higher risk of amputation and end-stage renal disease.
Treatment Approaches
Therapy: From "Relying Solely on Insulin" to "Multi-Pronged Precision Warfare"
Lifestyle: Still a "Prescription Drug"
* Diet: DASH, Mediterranean, and low-carb cycling plans, combined with continuous glucose monitoring (CGM) to "observe a curve with every bite."
* Exercise: 150 minutes of aerobic exercise + 2 resistance training sessions per week can reduce HbA1c by 0.7%.
Medications:
* Classic Upgrades: Metformin remains the first-line choice for type 2 diabetes; GLP-1 receptor agonists (such as semaglutide) offer a "triple threat" of lowering blood sugar, weight loss, and cardioprotection; SGLT2 inhibitors (such as dapagliflozin) promote glucose excretion through the kidneys.
* Ultra-Rapid/Long-Acting Insulin: Aspart insulin takes effect in 5 minutes; Icodec insulin is administered once a week.
* Oral GLP-1: Orforglipron is soon to be available, eliminating the need for injections.
Surgery:
* Metabolic Surgery (sleeve gastrectomy, bypass) - 70–90% remission rate at 1 year for type 2 diabetes patients with BMI ≥32.5 kg/m².
Technology:
* Artificial Pancreas: CGM + insulin pump closed-loop system, reducing nocturnal hypoglycemia by 40%.
* Continuous Glucose Monitoring (CGM): Blood glucose values every 5 minutes, with real-time alerts on mobile phones.
Cells and Genes:
* Stem Cell Islet Transplantation - A Chinese team utilizes chemical reprogramming to induce pluripotent stem cells; the first type 1 patient has been insulin-free for over a year.
* Gene Editing VCTX210: Stem cell islets with knocked-out immune recognition sites are in phase 1/2 clinical trials.
* Gene Therapy RJVA-001: A single dose of pancreatic-targeted GLP-1 expression, with blood sugar normalization in animal experiments lasting over 12 weeks.
Probiotics: A "New Weapon" Included in Consensus Guidelines
Probiotics improve glucose and lipid metabolism disorders by modulating gut microbiota structure, intestinal epithelial cell function, and the immune system.
* Mechanisms:
- Butyrate production → repairs the intestinal barrier → reduces LPS entry into the bloodstream.
- Induces GLP-1 secretion → increases early-phase insulin release.
- Inhibits the NF-κB inflammatory pathway → increases insulin receptor sensitivity.
Endogenous GLP-1 Secretion Can Improve Type 2 Diabetes
In the treatment of diabetes, glucagon-like peptide-1 (GLP-1), secreted by intestinal L cells, is an important target for treating type 2 diabetes. It can promote the endogenous secretion of insulin in a glucose-concentration-dependent manner. When blood sugar rises, GLP-1 binds to the GLP-1 receptors on pancreatic β-cells, stimulating insulin secretion and lowering blood sugar. At the same time, it can also inhibit the secretion of glucagon by pancreatic α-cells, further lowering blood sugar.
Probiotics like Bifidobacterium Animalis Subsp. lactis F1-7 and Lactiplantibacillus plantarum F3-2 can regulate the balance of gut microbiota, stimulate the intestine to secrete more GLP-1, thereby reducing or replacing the supplementation of exogenous GLP-1 drugs, endogenously promoting insulin production, adjusting blood sugar disorders in the body, and maintaining it within a normal and stable range.